MBX Biosciences (MBX) Change in Accured Expenses (2023 - 2026)

MBX Biosciences has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$4.9 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.9 million, down 970.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 million (down 66.64% YoY), and the FY2025 annual result was $6.8 million, up 114.32% from the prior year.
• Change in Accured Expenses came in at -$4.9 million for Q1 2026 at MBX Biosciences, down from $4.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q4 2025 to a low of -$4.9 million in Q1 2026.
• The 4-year median for Change in Accured Expenses is $177500.0 (2024), against an average of $392900.0.
• Across the five-year window, Change in Accured Expenses surged 2293.6% in 2025 and tumbled 970.43% in 2026, its largest moves.
• MBX Biosciences' Change in Accured Expenses stood at -$1.2 million in 2023, then soared by 82.81% to -$203000.0 in 2024, then soared by 2293.6% to $4.5 million in 2025, then sank by 209.07% to -$4.9 million in 2026.
• The last three Change in Accured Expenses figures came in at -$4.9 million (Q1 2026), $4.5 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.